MX374290B - Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. - Google Patents

Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.

Info

Publication number
MX374290B
MX374290B MX2016005801A MX2016005801A MX374290B MX 374290 B MX374290 B MX 374290B MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 374290 B MX374290 B MX 374290B
Authority
MX
Mexico
Prior art keywords
antibody
btk inhibitor
cancer
treatment
combination
Prior art date
Application number
MX2016005801A
Other languages
English (en)
Other versions
MX2016005801A (es
Inventor
Christian Klein
Yasuhiro Tomoko
Yoshizawa Toshio
Original Assignee
Ono Pharmaceutical Co
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Hoffmann La Roche filed Critical Ono Pharmaceutical Co
Publication of MX2016005801A publication Critical patent/MX2016005801A/es
Publication of MX374290B publication Critical patent/MX374290B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 con un inhibidor de BTK para el tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de BTK.
MX2016005801A 2013-11-07 2014-11-04 Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. MX374290B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07
PCT/EP2014/073640 WO2015067586A2 (en) 2013-11-07 2014-11-04 Combination therapy of an anti cd20 antibody with a btk inhibitor

Publications (2)

Publication Number Publication Date
MX2016005801A MX2016005801A (es) 2016-11-29
MX374290B true MX374290B (es) 2025-03-06

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005801A MX374290B (es) 2013-11-07 2014-11-04 Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.

Country Status (20)

Country Link
US (3) US20150125446A1 (es)
EP (1) EP3066126B1 (es)
JP (1) JP6478989B2 (es)
KR (1) KR101874215B1 (es)
CN (3) CN113995843A (es)
AR (1) AR098328A1 (es)
AU (1) AU2014345712B2 (es)
CA (1) CA2926893C (es)
ES (1) ES2728350T3 (es)
HK (1) HK1222803A1 (es)
IL (1) IL244960B (es)
MX (1) MX374290B (es)
MY (1) MY178726A (es)
NZ (1) NZ718792A (es)
PH (1) PH12016500839A1 (es)
PL (1) PL3066126T3 (es)
RU (1) RU2727650C2 (es)
TR (1) TR201907240T4 (es)
TW (1) TWI524899B (es)
WO (1) WO2015067586A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900549T1 (it) 2010-03-12 2019-11-13 Debiopharm Int Sa Molecole leganti il cd37 e loro immunoconiugati
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
BR122022001235B1 (pt) 2011-11-29 2023-04-11 Ono Pharmaceutical Co., Ltd Cristal de cloridrato derivado de purinona
EP3122360B1 (en) 2014-03-25 2020-06-17 ONO Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
DK3262071T3 (da) * 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
WO2016163531A1 (ja) 2015-04-09 2016-10-13 小野薬品工業株式会社 プリノン誘導体の製造方法
CN108472361B (zh) 2015-06-08 2022-12-27 德彪发姆国际有限公司 抗cd37免疫缀合物及抗cd20抗体组合物
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
TW201725044A (zh) * 2015-10-01 2017-07-16 基利科學股份有限公司 用於治療癌症之btk抑制劑及查核點抑制劑之組合
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TW201726130A (zh) * 2015-10-02 2017-08-01 基利科學股份有限公司 用於治療癌症之組合療法
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110869391A (zh) * 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
TWI772488B (zh) 2017-08-08 2022-08-01 瑞士商赫孚孟拉羅股份公司 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療
KR20210014684A (ko) 2018-05-30 2021-02-09 데비오팜 인터네셔날 에스 에이 항-cd37 면역접합체 투약 용법
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4110331B1 (en) * 2020-02-27 2024-11-06 BeiGene Switzerland GmbH Methods of treating dlbcl using btk inhibitors and combinations thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760562B2 (en) * 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
US7879984B2 (en) * 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
WO2011152351A1 (ja) * 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
KR20250086805A (ko) * 2011-10-19 2025-06-13 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
BR122022001235B1 (pt) * 2011-11-29 2023-04-11 Ono Pharmaceutical Co., Ltd Cristal de cloridrato derivado de purinona
EP2922827A4 (en) * 2012-11-20 2016-06-08 Celgene Avilomics Res Inc METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1

Also Published As

Publication number Publication date
HK1222803A1 (zh) 2017-07-14
MX2016005801A (es) 2016-11-29
KR20160079869A (ko) 2016-07-06
US20200171153A1 (en) 2020-06-04
EP3066126A2 (en) 2016-09-14
NZ718792A (en) 2020-05-29
AU2014345712A1 (en) 2016-05-05
RU2016122232A3 (es) 2018-06-18
JP2016536298A (ja) 2016-11-24
JP6478989B2 (ja) 2019-03-06
CA2926893A1 (en) 2015-05-14
US20150125446A1 (en) 2015-05-07
CA2926893C (en) 2022-04-12
WO2015067586A3 (en) 2015-07-30
IL244960A0 (en) 2016-05-31
TR201907240T4 (tr) 2019-06-21
AR098328A1 (es) 2016-05-26
TWI524899B (zh) 2016-03-11
CN114632158A (zh) 2022-06-17
PL3066126T3 (pl) 2019-08-30
PH12016500839A1 (en) 2016-06-13
US20250205333A1 (en) 2025-06-26
KR101874215B1 (ko) 2018-07-03
MY178726A (en) 2020-10-20
BR112016010271A2 (pt) 2017-10-03
EP3066126B1 (en) 2019-03-27
AU2014345712B2 (en) 2019-10-17
ES2728350T3 (es) 2019-10-23
IL244960B (en) 2021-08-31
RU2016122232A (ru) 2017-12-08
RU2727650C2 (ru) 2020-07-22
CN105792846A (zh) 2016-07-20
CN113995843A (zh) 2022-02-01
US12186392B2 (en) 2025-01-07
TW201521767A (zh) 2015-06-16
WO2015067586A2 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
MX374290B (es) Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
MX389342B (es) Un anticuerpo anti-cd20 en combinación con un inhibidor de bcl-2 y un inhibidor de mdm2 para usarse en el tratamiento de cáncer.
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX378546B (es) Combinaciones con anticuerpos anti-cd38 para usarse en el tratamiento de un sujeto que tiene una neoplasia maligna hematológica cd38-positivo
GEP20217331B (en) Anti-tigit antibodies
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
HUE065528T2 (hu) Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
TN2015000396A1 (en) Antibody drug conjugates
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2017005553A (es) Terapia de combinacion para cancer.
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2016002974A (es) Eteres de arilo y sus usos.
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
MX2015014501A (es) Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-farmaco.
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
CR20170537A (es) Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.

Legal Events

Date Code Title Description
FG Grant or registration